The entire hand includes the palm, back of the hands, and the fingers. The 4 g line is 4.5 inches long.
Select one or more newsletters to continue.
Due to its excellent tolerance, Voltaren Emulgel can be used for up to 14-21 days depending on the clinical situations. Diclofenac sodium is a white or slightly yellowish crystalline powder and is sparingly soluble in water at 25°C. Voltaren Emulgel has a cooling, moisturising effect with no strong odours. x�b```b``y��
Diclofenac sodium delayed-release tablets is a benzene-acetic acid derivative. Voltaren Gel should be gently massaged into the skin ensuring application to the entire affected hand, wrist, or elbow. In these patients, administration of an NSAID may cause a dose-dependent reduction in prostaglandin formation and, secondarily, in renal blood flow, which may precipitate overt renal decompensation.
Voltaren Gel is contraindicated in patients with previous serious skin reactions to NSAIDs Diclofenac may cause premature closure of the fetal ductus arteriosus.
The optimum times for making the first and subsequent transaminase measurements are not known.
Voltaren Gel was administered at a dose of 2 g per hand, 4 times daily, on both hands (16 g per day). Voltaren ® (diclofenac sodium enteric-coated tablets) is a benzene-acetic acid derivative. No overall differences in effectiveness or safety were observed between these subjects and younger subjects, but greater sensitivity to the effect of NSAIDs in some older individuals cannot be ruled out.Diclofenac, as with any NSAID, is known to be substantially excreted by the kidney, and the risk of toxic reactions to Voltaren Gel may be greater in patients with impaired renal function. 0000000934 00000 n
Other information about NSAIDs.
These maternally toxic doses were associated with dystocia, prolonged gestation, reduced fetal weights and growth, and reduced fetal survival.Based on available data, diclofenac may be present in human milk. In the setting of concomitant use of low-dose aspirin for cardiac prophylaxis, inform patients of the increased risk for and the signs and symptoms of GI bleeding Inform patients of the warning signs and symptoms of hepatotoxicity (e.g., nausea, fatigue, lethargy, pruritus, diarrhea, jaundice, right upper quadrant tenderness, and “flu-like” symptoms). You may have an increased risk of another heart attack if you take NSAIDs after a recent heart attack.Increased risk of bleeding, ulcers, and tears (perforation) of the esophagus (tube leading from the mouth to the stomach), stomach, and intestines:The risk of getting an ulcer or bleeding increases with:Before taking NSAIDS, tell your healthcare provider about all of your medical conditions, including if you:You should not take NSAIDs after 29 weeks of pregnancy.Tell your healthcare provider about all of the medicines you take, including prescription or over-the-counter medicines, vitamins or herbal supplements.Do not start taking any new medicine without talking to your healthcare provider first.See “What is the most important information I should know about medicines called Nonsteroidal Anti-inflammatory Drugs (NSAIDs)?Get emergency help right away if you get any of the following symptoms:Stop taking your NSAID and call your healthcare provider right away if you get any of the following symptoms:If you take too much of your NSAID, call your healthcare provider or get medical help right away.General information about the safe and effective use of NSAIDsImportant: Use the dosing card that is inside the Voltaren Gel carton to correctly measure each dose.
trailer
0000005749 00000 n
Skip side effects section. The molecular weight is 318.14. VOLTAREN ® GEL and analgesic doses of aspirin is not generally recommended (7) ACE Inhibitors, Angiotensin Receptor Blockers (ARB), or Beta-Blockers: Concomitant use with VOLTAREN ® GEL may diminish the antihypertensive effect of these drugs. The chemical name is 2-[(2,6-dichlorophenyl)amino] benzeneacetic acid, monosodium salt. Call your doctor for medical advice about side effects. Avoid use of NSAIDs, including Voltaren Gel, in pregnant women starting at 30 weeks of gestation (third trimester).There are no adequate and well-controlled studies of Voltaren Gel in pregnant women. 0000004542 00000 n
Do not use NSAIDs for a condition for which it was not prescribed. We comply with the HONcode standard for trustworthy health information - MedWatch Safety Alerts are distributed by the FDA and published by Drugs.com.
In this same cohort, the incidence of death in the first year post-MI was 20 per 100 person years in NSAID-treated patients compared to 12 per 100 person years in non-NSAID exposed patients.
Duration of exposure ranged from 8 to 12 weeks for the placebo-controlled studies, and up to 12 months for the open-label safety trial.In the placebo-controlled trials, the discontinuation rate due to adverse reactions was 5% for patients treated with Voltaren Gel, and 3% for patients in the placebo group.